{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-047832","form_type":"8-K","ticker":"RZLT","cik":"0001509261","company_name":"Rezolute, Inc.","filed_at":"2025-05-13T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.539243+00:00","generated_at":"2026-05-21T15:13:57.034365+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Rezolute Q3 net loss $18.9M; sunRIZE enrollment on track, BTD for ersodetug","bullets":["Cash $88.4M at March 31, 2025, down from $127.1M at June 30, 2024.","Phase 3 sunRIZE study enrollment expected to complete May 2025; topline results anticipated December 2025.","FDA granted Breakthrough Therapy Designation to ersodetug for tumor hyperinsulinism hypoglycemia in May 2025.","April 2025 underwritten offering raised ~$97M, extending cash runway to mid-2027.","Appointed Erik Harris (Ultragenyx CCO) to Board of Directors in March 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-047832","json":"https://secwatch.observer/filing/0001104659-25-047832.json","markdown":"https://secwatch.observer/filing/0001104659-25-047832.md","text":"https://secwatch.observer/filing/0001104659-25-047832.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1509261/000110465925047832/0001104659-25-047832-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1509261/000110465925047832/tm2514822d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-21T15:13:57.034365+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}